Pharmacodynamics of Levofloxacin in a Murine Pneumonia Model of Pseudomonas aeruginosa Infection: Determination of Epithelial Lining Fluid Targets
- 1 August 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (8) , 3325-3330
- https://doi.org/10.1128/aac.00006-09
Abstract
The dose choice for Pseudomonas aeruginosa remains a matter of debate. The actual exposure targets required for multilog killing of organisms at the primary infection site have not been delineated. We studied Pseudomonas aeruginosa PAO1 using a murine model of pneumonia. We employed a large mathematical model to fit all the concentration-time data in plasma and epithelial lining fluid (ELF) as well as colony counts in lung simultaneously for all drug doses. Penetration into ELF was calculated to be approximately 77.7%, as indexed to the ratio of the area under the concentration-time curve for ELF (AUC ELF ) to the AUC plasma . We determined the ELF concentration-time profile required to drive a stasis response as well as 1-, 2-, or 3-log 10 (CFU/g) kill. AUC/MIC ratios of 12.4, 31.2, 62.8, and 127.6 were required to drive these bacterial responses. Emergence of resistance was seen only at the two lowest doses (three of five animals at 50 mg/kg [body weight] and one of five animals at 100 mg/kg). The low exposure targets were likely driven by a low mutational frequency to resistance. Bridging to humans was performed using Monte Carlo simulation. With a 750-mg levofloxacin dose, target attainment rates fell below 90% at 4 mg/liter, 1 mg/liter, and 0.5 mg/liter for 1-, 2-, and 3-log kills, respectively. Given the low exposure targets seen with this strain, we conclude that levofloxacin at a 750-mg dose is not adequate for serious Pseudomonas aeruginosa pneumonia as a single agent. More isolates need to be studied to make these observations more robust.Keywords
This publication has 21 references indexed in Scilit:
- Association between Hypermutator Phenotype, Clinical Variables, Mucoid Phenotype, and Antimicrobial Resistance in Pseudomonas aeruginosaJournal of Clinical Microbiology, 2008
- In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection ModelsAntimicrobial Agents and Chemotherapy, 2008
- Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus StrainsAntimicrobial Agents and Chemotherapy, 2008
- Impact of Drug‐Exposure Intensity and Duration of Therapy on the Emergence ofStaphylococcus aureusResistance to a Quinolone AntimicrobialThe Journal of Infectious Diseases, 2007
- General informationJournal of the American Medical Directors Association, 2006
- Intrapulmonary Concentrations of Telithromycin: Clinical Implications for Respiratory Tract Infections due to Streptococcus pneumoniaeChemotherapy, 2005
- A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid–liquid extraction and reversed-phase HPLCJournal of Pharmaceutical and Biomedical Analysis, 2005
- Bacterial‐Population Responses to Drug‐Selective Pressure: Examination of Garenoxacin's Effect onPseudomonas aeruginosaThe Journal of Infectious Diseases, 2005
- Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogensDiagnostic Microbiology and Infectious Disease, 2005
- Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection ModelsAntimicrobial Agents and Chemotherapy, 2002